CBD and muscle insulin resistance: promise without proof
Cannabidiol and skeletal muscle insulin resistance: translational implications for exercise and rehabilitation medicine.
AI Summary
This narrative review examines whether cannabidiol (CBD) could affect skeletal muscle insulin resistance, a process involved in obesity, type 2 diabetes, metabolic syndrome, and related metabolic conditions. Because skeletal muscle is the main tissue that removes glucose from the blood in response to insulin, impaired muscle insulin action can affect both metabolic health and physical performance. Preclinical research suggests CBD may influence inflammation, oxidative stress, fat-related cellular damage, and ceramide accumulation—processes linked to insulin resistance.
However, the review emphasizes that evidence in humans is limited and inconsistent. Studies do not yet show reliable improvements in blood-sugar control or insulin sensitivity from CBD alone, and there is no clear evidence that it improves muscle function, exercise performance, or rehabilitation outcomes. For cannabis users, the practical message is that CBD should not currently be viewed as a proven treatment for insulin resistance or a replacement for exercise-based care. The authors describe it as a biologically plausible but clinically unproven experimental adjunct that requires well-designed clinical trials.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.